A carregar...
Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab
BACKGROUND: Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life‐threatening autoimmune thrombotic microangiopathy. Current standard of care is therapeutic plasma exchange, immunosuppression, and caplacizumab, an anti‐von Willebrand factor nanobody, which is effective in treating aTTP...
Na minha lista:
| Publicado no: | J Thromb Haemost |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7692904/ https://ncbi.nlm.nih.gov/pubmed/32757435 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jth.15045 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|